1. Introduction {#sec1}
===============

Liver cancer is one of the most common malignant tumors in the world \[[@B1]\]. It has a high degree of malignancy, strong invasion and metastasis, and poor prognosis and poses a serious threat to health \[[@B2]\]. Although the number of tumor markers used in the diagnosis and prognosis of related cancers has increased, none have the high recognition, sensitivity, and specificity required to evaluate the condition, efficacy, and prognosis of liver cancer \[[@B3], [@B4]\]. There is an urgent need to identify biomarkers with diagnostic and prognostic accuracy.

La ribonucleoprotein 4B (LARP4B) is a member of the La-related protein (LARP) family \[[@B5]\]. LARP4B protein is an RNA-binding protein containing lanthanum and adjacent RNA recognition motifs (RRMs) \[[@B6]\], which allow it to participate in posttranscriptional control of RNA and play an important role in translation \[[@B7], [@B8]\]. LARP4B is involved in the progression of many cancers \[[@B9]\]. In gliomas, for example, LARP4B inhibits tumor progression \[[@B10]\]. However, its role in liver cancer has not been explored.

To assess the potential clinical role of LARP4B in liver cancer, we probed TCGA database for the mRNA expression of *LARP4B* in liver cancer patients. Chi-squared testing was used to assess clinical relevance, ROC curves were used to estimate diagnostic capability, and overall/relapse-free survival analyses were conducted to examine the impact of LARP4B on patients with liver cancer. Univariate/multivariate Cox regression models were used to identify risk factors associated with liver cancer. We also carried out GSEA about the LARP4B-related signaling pathways.

2. Materials and Methods {#sec2}
========================

2.1. Data Source {#sec2.1}
----------------

We obtained currently available clinical and RNA sequence data about normal and liver cancer tissues from TCGA (<https://cancergenome.nih.gov/>). No ethical permission was required because all of the data used in this paper were made available for research.

2.2. Data Mining and Statistical Analyses {#sec2.2}
-----------------------------------------

We used the R software environment (version 3.6.1) for data mining \[[@B11]\]. Boxplots of clinical features were drawn with the ggplot2 package \[[@B12]\]. The ROC curve was drawn by pROC \[[@B13]\], which is based on a series of different binary classifications (demarcation value or determination threshold), plotting the true positive rate (sensitivity) as the ordinate and the false positive rate (1-specificity) as the abscissa. Among them, the area under the ROC curve (AUC) is used to measure the diagnostic performance. The chi-squared test was used to identify possible clinical correlations between clinical features and *LARP4B* expression. We also used survival packages to plot survival curves, and a logarithmic rank test to check survival bias \[[@B14]\]. Univariate and multivariate Cox models were used to distinguish risk factors associated with liver cancer \[[@B15]\].

2.3. GSEA {#sec2.3}
---------

GSEA is used to classify gene probes based on related biological pathways published in authoritative journals and coexpression data obtained from experiments. To determine correlation, a series of operations are carried out to determine whether the probes can reveal a distribution pattern of genes related to the phenotype of interest \[[@B16]\]. In this research, we used the gene set of "h.all.v6.2.symbols.gmt" from the Molecular Signatures Database to perform GSEA in GSEA 3.0 software. Through the analysis of 1,000 permutations, we obtained the standardized enrichment fraction and calculated a normalized enrichment score.

3. Results {#sec3}
==========

3.1. Data Overview {#sec3.1}
------------------

The *LARP4B* expression level and clinical features of the TCGA liver cancer cohort include gender, age, histologic type and grade, sample type, T/N/M classification, radiation therapy, residual tumor, vital status, stage, and relapse ([Table 1](#tab1){ref-type="table"}).

3.2. *LARP4B* Expression in Normal and Liver Cancer Tissues {#sec3.2}
-----------------------------------------------------------

Boxplots showed higher *LARP4B* mRNA expression in liver cancer tissues compared with normal liver tissues (*P* = 4*e*‐13; [Figure 1](#fig1){ref-type="fig"}). Furthermore, there were significant differences in *LARP4B* expression with regard to vital status (*P* = 0.03), stage (*P* = 0.0046), gender (*P* = 0.012), age (*P* = 0.0021), histologic grade (*P* = 0.00032), type (*P* = 0.0037), and T classification (*P* = 0.047).

3.3. Diagnostic Capability of *LARP4B* in Liver Cancer {#sec3.3}
------------------------------------------------------

ROC curves revealed that AUC was 0.816, indicating that *LARP4B* might have considerable diagnostic ability ([Figure 2(a)](#fig2){ref-type="fig"}). This result was confirmed in subsequent subgroup analysis of the different stages (AUC: 0.784, 0.795, 0.884, and 0.872 for stage I, stage II, stage III, and stage IV, respectively; Figures [2(b)](#fig2){ref-type="fig"}--[2(e)](#fig2){ref-type="fig"}).

3.4. High *LARP4B* Expression Was Relevant to Clinical Features of Liver Cancer {#sec3.4}
-------------------------------------------------------------------------------

As shown in [Table 2](#tab2){ref-type="table"}, the expression of *LARP4B* was clearly related to age (*P* = 0.0274), gender (*P* = 0.0256), vital status (*P* = 0.0301), and histologic grade (*P* = 0.0003) of liver cancer patients.

3.5. Increased *LARP4B* Expression Was Related to Poor Overall Survival in Liver Cancer {#sec3.5}
---------------------------------------------------------------------------------------

As shown in [Figure 3](#fig3){ref-type="fig"}, the high expression of *LARP4B* in patients was correlated with poor overall survival (*P* = 0.0095). Subgroup analysis showed that *LARP4B* expression had significant prognostic value in liver cancer patients who were older (*P* = 0.0049), T3 (*P* = 0.012), G1/G2 (*P* = 0.016), male (*P* = 0.01), and R0 (*P* = 0.013).

A univariate Cox model revealed that residual tumor, stage, T classification, and *LARP4B* expression represented potential survival-related variables. A multivariate Cox model suggested that a high *LARP4B* expression was a potential independent risk factor for patient\'s overall survival with liver cancer (95% confidence interval (CI) 1.1--2.46, *P* = 0.016, hazard ratio (HR) = 1.64; [Table 3](#tab3){ref-type="table"}).

3.6. Increased *LARP4B* Expression Was Related to Poor Relapse-Free Survival in Liver Cancer {#sec3.6}
--------------------------------------------------------------------------------------------

As shown in [Figure 4](#fig4){ref-type="fig"}, there was a high expression of *LARP4B* in patients with relapse-free survival (*P* = 0.044). Subgroup analysis showed that *LARP4B* expression had a prognostic value in liver cancer patients who were T4 (*P* = 0.049), male (*P* = 0.014), stage III/IV (*P* = 0.037), G1/G2 (*P* = 0.022), and older (*P* = 0.024).

A univariate Cox model showed that residual tumor, stage, T classification, and *LARP4B* expression represented potential relapse-free survival-related variables. A multivariate Cox model suggested that a high *LARP4B* expression was a potential independent risk factor for relapse-free survival in liver cancer patients (95% CI 1--2.13, *P* = 0.048, HR = 1.46; [Table 4](#tab4){ref-type="table"}).

3.7. LARP4B-Related Signaling Pathway {#sec3.7}
-------------------------------------

To identify the activated signal pathways in liver cancer, GSEA was conducted between the low *LARP4B* expression and high *LARP4B* expression datasets. GSEA revealed significant differences in the enrichment of the MSigDB Collection (h.all.v6.2.symbols.gmt; NOM *P* value \< 0.05, FDR \< 0.25; [Table 5](#tab5){ref-type="table"}). Genes related to E2F, G2M, and the mitotic spindle ([Figure 5](#fig5){ref-type="fig"}; [Table 5](#tab5){ref-type="table"}) were enriched in the high LARP4B expression phenotype, which may represent an intrinsic mechanism of poor prognosis.

4. Discussion {#sec4}
=============

Viral infection, diet, environmental problems, and other factors have contributed to the high mortality rate of liver cancer worldwide \[[@B17]\]. Continuous advances in surgical technology, chemotherapeutic drugs, and molecular biology have furthered our understanding of cancer biology, and there has been great progress in the treatment of liver cancer in recent years. In this study, we have applied our extensive experience in the exploration of novel biomarkers \[[@B18]--[@B23]\] to identify a biomarker, LARP4B, for the diagnosis and prognosis of patients with liver cancer.

The involvement of LARP4B has been documented in many cancer processes, including medulloblastoma \[[@B24]\], malignant peripheral nerve sheath tumors \[[@B25]\], colorectal cancer \[[@B26]\], pancreatic cancer \[[@B27]\], and glioma \[[@B10]\]. In contrast to our results, Koso et al. \[[@B10]\] found low expression of LARP4B in gliomas, which suggests that LARP4B may play different roles in different cancers. In addition, the boxplots showed that *LARP4B* expression was statistically significantly associated with vital status, age, gender, histologic grade and type, stage, and T classification. Therefore, it is necessary to further explore the role of LARP4B in liver cancer.

Low LARP4B expression was closely related to poor prognosis in glioma cancer patients in the study by Koso et al. \[[@B10]\]. No such relationship between LARP4B and prognosis has been found in liver cancer. In this study, we found that overexpressed *LARP4B* was associated with a poor prognosis in liver cancer patients, which may be attributable to the different functions of LARP4B in different tissues. LARP4B overexpression also led to shorter overall/relapse-free survival. Subgroup analysis of overall survival showed especially poor prognoses in patients who were male, T3, G1/G2, older, and R0, while relapse-free survival was correlated with patients who were male, T4, G1/G2, older, and stage III/IV. This distinction could be applied to the precise, individualized treatment of liver cancer patients. Calculation of AUC from the ROC curves showed the validity of clinical diagnostic testing of LARP4B. Our results suggest that LARP4B has strong potential as a marker in the clinical detection of liver cancer patients.

The progression of cancer requires a complete cell cycle \[[@B28]\]. Genes related to E2F, G2M, and the mitotic spindle are important signaling pathways in the cell cycle \[[@B29]--[@B31]\]. Interestingly, we found that E2F, G2M, and mitotic spindle signaling pathways were all involved in the progression of liver cancer. LARP4B is a posttranscriptional regulator and may regulate the roles of downstream genes through these three sets of target molecules. In addition, Zhang et al. \[[@B32]\] found that LARP4B may regulate the cell cycle of leukemia stem cells by inhibiting the expression of cell cycle inhibitors p16, P19, and p21 and myeloid-specific transcription factor CCAAT enhancer binding protein alpha. However, Mattijssen and Maraia \[[@B33]\] found that LARP4B participated in the regulation of TNF-alpha-TTP as its functional activity in MLL-AF9 leukemia stem cells. It is possible that LARP4B participates in the progression of different cancers through multiple signaling pathways.

As far as we know, this is the first study to examine the diagnostic and prognostic values of *LARP4B* expression in liver cancer. Together with other studies on the functions of LARP4B, we have contributed to a better understanding of the role of LARP4B and expanded the possibilities for more precise diagnosis and prognosis in cancer. We plan to continue exploring the functions of LARP4B to clarify its underlying mechanism in tumorigenesis at a deeper level.

5. Conclusion {#sec5}
=============

In this investigation of LARP4B in the prognosis and diagnosis of liver cancer, we identified high LARP4B expression as a potential independent biomarker for negative prognosis. We have plans for complex experiments to explore the mechanism further.
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###### 

Demographic and clinical characteristics of the TCGA-LIHC cohort.

  Characteristics                     Number of cases (%)
  ----------------------------------- ---------------------
  Age                                 
   \<55                               117 (31.45)
   ≥55                                255 (68.55)
   NA                                 1 (0)
  Gender                              
   Female                             121 (32.44)
   Male                               252 (67.56)
  Histological type                   
   Fibrolamellar carcinoma            3 (0.8)
   Hepatocellular carcinoma           363 (97.32)
   Hepatocholangiocarcinoma (mixed)   7 (1.88)
  Histologic grade                    
   NA                                 5 (1.34)
   G1                                 55 (14.75)
   G2                                 178 (47.72)
   G3                                 123 (32.98)
   G4                                 12 (3.22)
  Stage                               
   NA                                 24 (6.43)
   I                                  172 (46.11)
   II                                 87 (23.32)
   III                                85 (22.79)
   IV                                 5 (1.34)
  T classification                    
   NA                                 2 (0.54)
   T1                                 182 (48.79)
   T2                                 95 (25.47)
   T3                                 80 (21.45)
   T4                                 13 (3.49)
   TX                                 1 (0.27)
  N classification                    
   NA                                 1 (0.27)
   N0                                 253 (67.83)
   N1                                 4 (1.07)
   NX                                 115 (30.83)
  M classification                    
   M0                                 267 (71.58)
   M1                                 4 (1.07)
   MX                                 102 (27.35)
  Radiation therapy                   
   NA                                 25 (6.7)
   No                                 340 (91.15)
   Yes                                8 (2.14)
  Residual tumor                      
   NA                                 7 (1.88)
   R0                                 326 (87.4)
   R1                                 17 (4.56)
   R2                                 1 (0.27)
   RX                                 22 (5.9)
  Vital status                        
   Deceased                           130 (34.85)
   Living                             243 (65.15)
  Sample type                         
   Primary tumor                      371 (99.46)
   Recurrent tumor                    2 (0.54)
  LARP4B                              
   High                               253 (67.83)
   Low                                120 (32.17)

Abbreviation: NA: not available.

###### 

Correlation between the expression of LARP4B and the clinic pathologic characteristics in liver cancer.

  Clinical characteristics           Variable                  No. of patients   LARP4B expression   *X* ^2^   *P*                       
  ---------------------------------- ------------------------- ----------------- ------------------- --------- ------- ------- --------- --------
  Age                                \<55                      117               89                  35.32     28      23.33   4.8736    0.0273
  ≥55                                255                       163               64.68               92        76.67                     
  Gender                             Female                    121               92                  36.36     29      24.17   4.9824    0.0256
  Male                               252                       161               63.64               91        75.83                     
  Histological type                  Fibrolamellar carcinoma   3                 3                   1.19      0       0       4.8737    0.0874
  Hepatocellular carcinoma           363                       243               96.05               120       100                       
  Hepatocholangiocarcinoma (mixed)   7                         7                 2.77                0         0                         
  Histologic grade                   G1                        55                27                  10.8      28      23.73   18.9592   0.0003
  G2                                 178                       115               46                  63        53.39                     
  G3                                 123                       98                39.2                25        21.19                     
  G4                                 12                        10                4                   2         1.69                      
  Stage                              I                         172               108                 45.96     64      56.14   4.4368    0.218
  II                                 87                        59                25.11               28        24.56                     
  III                                85                        64                27.23               21        18.42                     
  IV                                 5                         4                 1.7                 1         0.88                      
  T classification                   T1                        182               117                 46.25     65      55.08   6.9572    0.1382
  T2                                 95                        66                26.09               29        24.58                     
  T3                                 80                        62                24.51               18        15.25                     
  T4                                 13                        8                 3.16                5         4.24                      
  TX                                 1                         0                 0                   1         0.85                      
  N classification                   N0                        253               174                 69.05     79      65.83   2.6345    0.2679
  N1                                 4                         4                 1.59                0         0                         
  NX                                 115                       74                29.37               41        34.17                     
  M classification                   M0                        267               188                 74.31     79      65.83   3.2303    0.1989
  M1                                 4                         3                 1.19                1         0.83                      
  MX                                 102                       62                24.51               40        33.33                     
  Radiation therapy                  No                        340               233                 97.08     107     99.07   0.5773    0.4474
  Yes                                8                         7                 2.92                1         0.93                      
  Residual tumor                     R0                        326               223                 88.49     103     90.35   2.9922    0.3928
  R1                                 17                        12                4.76                5         4.39                      
  R2                                 1                         0                 0                   1         0.88                      
  RX                                 22                        17                6.75                5         4.39                      
  Sample type                        Primary tumor             371               252                 99.6      119     99.17   0         1
  Recurrent tumor                    2                         1                 0.4                 1         0.83                      
  Vital status                       Deceased                  130               98                  38.74     32      26.67   4.7032    0.0301
  Living                             243                       155               61.26               88        73.33                     

###### 

Summary of univariate and multivariate Cox regression analyses of overall survival duration.

  Parameters          Univariate analysis   Multivariate analysis                              
  ------------------- --------------------- ----------------------- ------- ------ ----------- -------
  Age                 1                     0.69-1.45               0.997                      
  Gender              0.8                   0.56-1.14               0.22                       
  Histological type   0.99                  0.27-3.66               0.986                      
  Histologic grade    1.04                  0.84-1.3                0.698                      
  Stage               1.38                  1.15-1.66               0.001   0.87   0.7-1.08    0.203
  T classification    1.66                  1.39-1.99               0       1.85   1.46-2.34   0
  N classification    0.73                  0.51-1.05               0.086                      
  M classification    0.72                  0.49-1.04               0.077                      
  Radiation therapy   0.51                  0.26-1.03               0.06                       
  Residual tumor      1.42                  1.13-1.8                0.003   1.39   1.08-1.78   0.01
  LARP4B              1.69                  1.13-2.52               0.01    1.64   1.1-2.46    0.016

###### 

Summary of univariate and multivariate Cox regression analyses of relapse-free survival duration.

  Parameters          Univariate analysis   Multivariate analysis                              
  ------------------- --------------------- ----------------------- ------- ------ ----------- -------
  Age                 0.9                   0.63-1.28               0.55                       
  Gender              0.99                  0.7-1.41                0.966                      
  Histological type   2.02                  0.66-6.24               0.22                       
  Histologic grade    0.98                  0.8-1.21                0.883                      
  Stage               1.66                  1.38-1.99               0       1.12   0.87-1.44   0.392
  T classification    1.78                  1.49-2.12               0       1.67   1.28-2.17   0
  N classification    0.97                  0.67-1.4                0.874                      
  M classification    1.17                  0.79-1.74               0.432                      
  Radiation therapy   0.74                  0.26-2.16               0.584                      
  Residual tumor      1.28                  1.01-1.61               0.042   1.31   1.03-1.67   0.026
  LARP4B              1.46                  1.01-2.11               0.045   1.46   1-2.13      0.048

###### 

Gene sets enriched in phenotype high.

  MSigDB collection        Gene set name              NES         NOM *p* val   FDR *q* val
  ------------------------ -------------------------- ----------- ------------- -------------
  h.all.v6.2.symbols.gmt   HALLMARK_MITOTIC_SPINDLE   -1.846927   0.005917      0.205141
  h.all.v6.2.symbols.gmt   HALLMARK_G2M_CHECKPOINT    -1.710802   0.016293      0.255083
  h.all.v6.2.symbols.gmt   HALLMARK_E2F_TARGETS       -1.583288   0.045643      0.40425

Notes: gene sets with NOM *P* value \< 0.05 and FDR *q* value \< 0.25 are considered as significant. Abbreviations: FDR: false discovery rate; NES: normalized enrichment score; NOM: nominal.
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